查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1736748

2026-2032 年體外膜氧合市場（按零件、服務、病患類型、應用和地區分類）

Extracorporeal Membrane Oxygenation Machine Market By Component (Pumps, Cannula), By Services (Veno-Venous, Veno-Arterial), By Patient Type (Adult, Pediatric), By Application (Respiratory, ECPR), And Region for 2026-2032
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

體外膜氧合（ECMO）市場評估-2026-2032

先進感測器和監測系統的不斷發展和應用，能夠即時評估和追蹤患者參數，推動了體外膜氧合市場的成長。醫療保健產業的成長，尤其是在新興地區的成長，為體外膜氧合市場創造了新的機會，預計2024年該市場的估值將超過6.2323億美元，到2032年將達到約9.3281億美元。

此外，技術進步也提升了醫護人員使用ECMO設備的實踐，促進了ECMO設備在各種臨床環境中的廣泛應用。這項技術提高了患者的存活率，預計2026年至2032年期間，該利基市場的複合年成長率將達到5.75%。

體外膜氧合市場定義/概述

體外膜氧合技術是指血液經由心肺機進行體外循環。這種方法可以有效去除二氧化碳，同時將富氧血液送回循環系統。血液經心臟右側流入心肺機。之後，血液被重新加熱並返回體內。

ECMO 是指將病患的血液引導至體外循環，使其氧合併去除二氧化碳，然後再回到體內。 ECMO 常用於治療嚴重心臟衰竭、呼吸衰竭（例如急性呼吸窘迫症候群 (ARDS) 和肺炎）以及心血管手術後的併發症。 ECMO 擴大應用於新生兒和兒科護理，顯著提高了患有先天性缺陷和嚴重呼吸窘迫的嬰兒的存活率。 ECMO 能夠暫時接管衰竭器官的功能，為醫生提供了一個關鍵的窗口，以穩定患者病情並解決功能障礙的根本原因。

心臟病和呼吸系統疾病發生率的不斷上升如何推動市場擴張？

心肺疾病的發生率不斷上升是一個重大問題，凸顯了加強醫療干預措施（包括體外膜氧合 (ECMO) 設備）的必要性。由於人口老化、久坐不動的生活方式、不良飲食習慣以及高血壓、肥胖和糖尿病等危險因素的日益普遍，心臟衰竭、心肌梗塞和心臟麻痹等心臟疾病的發病率正在上升。由於這些疾病通常會導致危及生命的狀況，而傳統治療方法無法奏效，因此，ECMO 系統在治療潛在疾病的同時，透過維持氧合和循環功能，已成為維持生命的必要手段。

急性呼吸窘迫症候群(ARDS) 的特徵是肺部小氣囊內積液，抑制氧氣有效輸送至血液。 ARDS 可能發展為嚴重的呼吸系統疾病，需要外部輔助才能獲得有效的呼吸支持。心源性休克是一種嚴重的疾病，其特徵是心臟突然無法有效泵血以滿足身體需求，如果不及時處理，可能導致器官衰竭。

患者數量的不斷成長推動了對體外膜氧合（ECMO）設備的需求。 ECMO設備可以替代心臟和肺部，使這些重要器官休息和恢復。對於加護病房中那些對其他療法無效的患者，這項技術已成為必不可少的治療手段。心肺疾病盛行率的不斷上升是影響ECMO設備市場的關鍵因素。

ECMO 設備和程序相關成本的上升是否會阻礙市場擴張？

體外膜氧合機（ECMO）在維持心臟衰竭衰竭患者生命方面發揮著至關重要的作用。 ECMO設備成本高昂，通常高達數十萬人事費用，是其關鍵問題之一。此外，這種治療方法需要高度專業的醫療團隊，包括訓練有素的灌注師、加護病房(ICU) 工作人員以及持續的患者監測，這增加了人員成本，並限制了能夠提供ECMO治療的醫院數量。

這是因為其製造過程中採用了最尖端科技和創新材料。總成本也受到這些機器相關的維護和營運費用的影響。 ECMO治療需要由外科醫生、護士和鼓膜技師組成的醫療專業團隊，這會增加治療總成本。

目錄

第 1 章全球體外膜氧合市場簡介

  • 市場定義
  • 市場區隔
  • 調查時間表
  • 先決條件
  • 限制

第 2 章 已驗證的市場研究調查方法

  • 資料探勘
  • 數據三角測量
  • 自下而上的方法
  • 自上而下的方法
  • 調查流程
  • 業界專家的重要見解
  • 資料來源

第3章執行摘要

  • 市場概覽
  • 生態測繪
  • 絕對的商機
  • 市場吸引力
  • 全球體外膜氧合裝置市場區域分析
  • 全球體外膜氧合裝置市場（按患者類型分類）（百萬美元）
  • 全球體外膜氧合裝置市場（按應用分類）（百萬美元）
  • 全球體外膜氧合裝置市場（按類型分類）（百萬美元）
  • 全球體外膜氧合裝置市場（按組件分類）（百萬美元）
  • 未來市場機會
  • 全球市場區隔
  • 產品生命線

第4章 體外膜氧合裝置全球市場展望

  • 體外膜氧合的全球演變
  • 驅動程式
    • 促進要素1
    • 促進要素2
  • 限制因素
    • 約束因素 1
    • 約束因素 2
  • 機會
    • 機會1
    • 機會2
  • 波特五力模型
  • 價值鏈分析
  • 定價分析
  • 宏觀經濟分析

5. 全球體外膜氧合裝置市場（按部分）

  • 概述
  • 泵浦
  • 套管
  • 氧氣供應
  • 配件
  • 控制器

6. 全球體外膜氧合裝置市場（依服務）

  • 概述
  • 靜脈-動脈
  • 靜脈-維納斯
  • 動脈-金星

7. 全球體外膜氧合裝置市場（依患者型態）

  • 概述
  • 成人
  • 孩子們
  • 新生兒

8. 全球體外膜氧合裝置市場（依應用）

  • 概述
  • 呼吸系統
    • 新生兒
    • 孩子們
    • 成人
  • 心肺復甦
    • 新生兒
    • 孩子們
    • 成人
  • 心
    • 新生兒
    • 孩子們
    • 成人

9. 全球體外膜氧合裝置市場（按地區）

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 中東和非洲
    • 阿拉伯聯合大公國
    • 沙烏地阿拉伯
    • 南非
    • 其他中東和非洲地區

第10章體外膜氧合裝置市場的全球競爭格局

  • 概述
  • 企業市場排名
  • 公司地理分佈
  • 公司產業佈局
  • ACE矩陣

第11章 公司簡介

  • Medtronic
  • Fresenius Medical Care AG & Co. KGAA
  • Maquet Holding
  • Getinge Group
  • Microport
  • Origin Biomedical
  • Terumo Cardiovascular Systems Corporation
  • Livanova plc
  • Nipro Corporation
  • Euro sets SRL

第 12 章 已驗證的市場情報

  • 關於已驗證的市場情報
  • 動態資料視覺化
簡介目錄
Product Code: 40614

Extracorporeal Membrane Oxygenation Machine Market Valuation - 2026-2032

The growing advancements and the utilization of sophisticated sensor and monitoring systems enabling the real-time assessment and tracking of patient parameters is driving the growth of the Extracorporeal Membrane Oxygenation Machine Market. The growth of the healthcare industry, particularly in developing regions, is creating new opportunities for the ECMO market, surpassing USD 623.23 Million valued in 2024 to reach a valuation of around USD 932.81 Million by 2032.

In addition to this, the advancements in technology are enhancing the practice of healthcare professionals in the use of ECMO machines, thereby contributing to an increased utilization of these machines across diverse clinical environments. This technology is consequently leading to an increase in patient survival rates, enabling the niche market grow at a CAGR of 5.75% from 2026 to 2032.

Extracorporeal Membrane Oxygenation Machine Market: Definition/ Overview

The extracorporeal membrane oxygenation machine (ECMO) involves the external circulation of blood through a heart-lung machine. The device effectively eliminates carbon dioxide while delivering oxygen-enriched blood back to the circulatory system. The right side of the heart directs blood flow to the heart-lung machine. The substance is subsequently reheated and returned to the body.

ECMO works by channeling the patient's blood through an external circuit where it is oxygenated and carbon dioxide is removed before being returned to the body. It is commonly used in cases of severe cardiac failure, respiratory failure (such as ARDS or pneumonia), or post-cardiac surgery complications. ECMO is increasingly being applied in neonatal and pediatric care, where it has significantly improved survival rates for infants with congenital defects or severe respiratory distress. Its ability to temporarily take over the function of failing organs offers physicians a critical window to stabilize patients and address underlying causes of failure.

How are the Rising Incidence of Cardiac and Respiratory Conditions Propelling the Market Expansion?

The increasing prevalence of cardiopulmonary disorders is a significant issue, highlighting the necessity for enhanced medical interventions, including ECMO machines. Cardiac diseases, such as heart failure, myocardial infarction, and cardiac arrest, are on the rise due to factors like aging populations, sedentary lifestyles, poor diets, and increasing prevalence of risk factors such as hypertension, obesity, and diabetes. As these conditions often lead to life-threatening situations where traditional treatments may not suffice, ECMO systems are becoming essential in providing life support by maintaining oxygenation and circulatory functions while underlying conditions are treated.

Acute respiratory distress syndrome (ARDS) is characterized by the accumulation of fluid in the small air sacs of the lungs, impeding the efficient transfer of oxygen into the bloodstream. There is potential for escalation to severe respiratory issues, necessitating external assistance for effective breathing support. Cardiogenic shock represents a severe medical condition characterized by the heart's abrupt inability to effectively pump sufficient blood to meet the body's demands, leading to potential organ failure if not addressed promptly.

The rising patient population is leading to an escalating demand for ECMO machines. ECMO machines serve as substitutes for the heart and lungs, facilitating a period of rest and recovery for these vital organs. This technology has become essential in the intensive care unit for managing patients who do not respond to alternative treatments. The increasing prevalence of cardiopulmonary disorders is a significant factor influencing the ECMO machine market.

How Will the Elevated Expenses Associated with ECMO Machines and Procedures Hinder the Market Expansion?

The extracorporeal membrane oxygenation machine serves as a critical life support mechanism for individuals experiencing heart or lung failure. The core issue is that the substantial costs associated with ECMO machines, often reaching hundreds of thousands, represent a significant barrier to their utilization despite their remarkable capabilities. The procedure also requires highly specialized medical teams, including trained perfusionists, intensive care unit (ICU) staff, and continuous patient monitoring, which adds to labor costs and limits the number of hospitals capable of offering ECMO treatment.

This results from the utilization of cutting-edge technology and innovative materials in its production process. The overall cost is further influenced by the maintenance and operational expenses associated with these machines. ECMO procedures necessitate specialized teams of healthcare professionals, comprising surgeons, nurses, and percussionists, which contribute to the total treatment expenses.

Category-Wise Acumens

What are the Features Bolstering the Demand of Oxygenators Segment?

The oxygenators segment represented the most dominating segment in 2023 and is projected to continue its dominance throughout the forecast period. The rise in chronic diseases, particularly Chronic Obstructive Pulmonary Disease (COPD), alongside the growing need for heart and lung transplantation procedures, can explain this trend. The World Health Organization (WHO) reported that COPD ranked as the third leading cause of death worldwide, accounting for roughly 3.23 million fatalities. The significant increase in mortality rates associated with respiratory and cardiovascular diseases is driving the expansion of the Extracorporeal Membrane Oxygenation Machine Market.

The oxygenators segment is expected to benefit from the overall advancements in ECMO technology and its expanding use in broader clinical settings, including emergency and pediatric care. As healthcare systems adopt ECMO for more patients with severe cardiac and respiratory conditions, demand for high-performance oxygenators will likely increase. Furthermore, ongoing research into biocompatibility and longevity of oxygenators is set to improve patient outcomes and reduce the risks associated with long-term ECMO use, solidifying the market dominance of this segment.

How will the Demand for Veno-Arterial Segment Impacts the Market Growth?

The veno-arterial segment represented the fastest growing CAGR in 2023 and is projected to experience robust growth at a healthy CAGR throughout the forecast period. The increase in utilization can be linked to its effectiveness in managing cases of cardiac arrest, where it plays a crucial role in algorithm-driven life support techniques aimed at reestablishing blood circulation. The rising prevalence of chronic obstructive pulmonary disease (COPD) serves as a significant factor influencing this market segment. A research paper published by BMC Pulmonary Medicine in July 2022 indicated that around 300 million individuals are affected by COPD worldwide, with a prevalence rate of about 12.2%. This underscores a considerable demand for advanced life support technologies such as ECMO machines.

Innovations in VA-ECMO technology, such as more compact and efficient devices, and the integration of real-time monitoring systems, are likely to make it more accessible in emergency care and for long-term patient management. Moreover, expanding use in treating adult and pediatric patients with complex cardiac conditions, combined with advancements in postoperative recovery, will further drive the growth of this segment across hospitals and specialized care centers during the forecast period.

Country/Region-wise Acumens

How will the Growing Cardiac Issues Drives the Market in North America?

In 2023, the North America Extracorporeal Membrane Oxygenation Machine Market had the dominating share in terms of global revenues. North American market was predominantly represented by the U.S., which held the largest share in the global market. The nation possesses a robust healthcare infrastructure and a significant patient demographic in need of ECMO machines, attributed to the widespread occurrence of chronic illnesses and a notable rate of cardiac and respiratory failures. This has led to a higher demand for advanced life support systems like ECMO, particularly the veno-arterial (VA) type, which provides both cardiac and respiratory assistance in patients suffering from severe cardiac failure. With increasing numbers of patients requiring urgent intervention for heart-related complications, hospitals and medical centers are increasingly adopting ECMO technology as a critical tool for improving survival rates.

The U.S. has maintained its position as a global leader in the innovation of medical devices, drawing in leading manufacturers of ECMO machines. Major market players such as Medtronic, a prominent player in the medical technology sector, has achieved notable advancements in the ECMO machine market. The active participation of the U.S. in the development and approval processes for ECMO machines has led to a notable rise in adoption and expansion within this market segment.

How will the Increasing Adoption of Precision Medicine Supports the Market Growth in China?

Asia-Pacific region to grow at a robust CAGR during the forecast period. China is projected to maintain a leading role in the East Asia market for extracorporeal membrane oxygenation machines. The increasing utilization of ECMO in pediatric and neonatal care represents a significant factor influencing the industry in China. The evolving healthcare sector in the country is increasingly focused on improving clinical outcomes for infants and children suffering from life-threatening cardiorespiratory conditions.

In cases involving congenital heart defects, respiratory distress syndrome, and various severe infections in neonates, ECMO serves as a critical intervention when standard treatment options are inadequate. China is channeling investments into specialized pediatric and neonatal intensive care units across major hospitals, with ECMO machines emerging as essential equipment. The demand in China is driven by the government's dedication to enhancing health services for children, alongside the growing awareness among healthcare professionals regarding the effectiveness of ECMO in pediatric care.

Competitive Landscape

The Extracorporeal Membrane Oxygenation Machine Market is a dynamic and competitive landscape, with a mix of established players and emerging challengers vying for market share. These players are actively working to strengthen their presence by implementing strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations are dedicated to continuously improving their product line to meet the needs of a wide range of customers in different regions.

Some of the key players operating in the Extracorporeal Membrane Oxygenation Machine Market include:

Medtronic, Fresenius Medical Care A.G. & Co. KGAA, Maquet Holding, Getinge Group, Microport, Origin Biomedical, Terumo Cardiovascular Systems Corporation, Livanova plc, Nipro Corporation, Euro sets S.R.L., Cytosorbents Corporation, Abiomed.

Latest Developments

In July 2023, the ASAIO Conference showcased BreathMo, an advanced ECMO system, highlighting China's innovation in the field of medical technology. This innovative maglev technology effectively meets the specific medical requirements of patients in China, representing a significant progression in the sector.

In April 2023, Abbott obtained two new approvals from the U.S. Food and Drug Administration (FDA) for its renowned life support system, specifically the CentriMag Blood Pump. The expanded FDA indication facilitates prolonged utilization in adults based on extracorporeal membrane oxygenation (ECMO), an essential life support technique for individuals experiencing cardiac and pulmonary complications.

In November 2022, LivaNova PLC announced that it had received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its next-generation advanced circulatory support system, LifeSPARC. The approval indicates that the LifeSPARC system complies with the standards established by the FDA, allowing for its utilization in the U.S. market.

In July 2022, Inspira Technologies OXY B.H.N Ltd., a leader in life support technology, launched the "Liby" System. This sophisticated life support system is engineered to manage patients experiencing critical heart and lung failure.

In July 2021, Xenios AG, a subsidiary of Fresenius Medical Care, obtained approval from the National Medical Products Administration (NMPA) in China for the utilization of its Xenios Console and patient kits in ECMO therapy. The approval follows the successful registration of two patient kits in China.

Extracorporeal Membrane Oxygenation Machine Market, By Category

  • Component:
  • Pumps
  • Oxygenator
  • Controllers
  • Cannula
  • Accessories
  • Services:
  • Veno-Venous
  • Veno-Arterial
  • Arterio-Venous
  • Patient Type:
  • Neonates
  • Pediatric
  • Adult
  • Application:
  • Respiratory
  • Neonates
  • Pediatric
  • Adult
  • Cardiac
  • Neonates
  • Pediatric
  • Adult
  • ECPR
  • Neonates
  • Pediatric
  • Adult
  • Region:
  • North America
  • Asia-Pacific
  • Europe
  • South America
  • Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL EXTRACORPOREAL MEMBRANE OXYGENATION MACHINE MARKET

  • 1.1 Market Definition
  • 1.2 Market Segmentation
  • 1.3 Research Timelines
  • 1.4 Assumptions
  • 1.5 Limitations

2 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 2.1 Data Mining
  • 2.2 Data Triangulation
  • 2.3 Bottom-Up Approach
  • 2.4 Top-Down Approach
  • 2.5 Research Flow
  • 2.6 Key Insights from Industry Experts
  • 2.7 Data Sources

3 EXECUTIVE SUMMARY

  • 3.1 Market Overview
  • 3.2 Ecology Mapping
  • 3.3 Absolute Market Opportunity
  • 3.4 Market Attractiveness
  • 3.5 Global Extracorporeal Membrane Oxygenation Machine Market Geographical Analysis (CAGR %)
  • 3.6 Global Extracorporeal Membrane Oxygenation Machine Market, By Patient Type (USD Million)
  • 3.7 Global Extracorporeal Membrane Oxygenation Machine Market, By Application (USD Million)
  • 3.8 Global Extracorporeal Membrane Oxygenation Machine Market, By Modality (USD Million)
  • 3.9 Global Extracorporeal Membrane Oxygenation Machine Market, By Component (USD Million)
  • 3.10 Future Market Opportunities
  • 3.11 Global Market Split
  • 3.12 Product Life Line

4 GLOBAL EXTRACORPOREAL MEMBRANE OXYGENATION MACHINE MARKET OUTLOOK

  • 4.1 Global Extracorporeal Membrane Oxygenation Machine Evolution
  • 4.2 Drivers
    • 4.2.1 Driver1
    • 4.2.2 Driver 2
  • 4.3 Restraints
    • 4.3.1 Restraint1
    • 4.3.2 Restraint 2
  • 4.4 Opportunities
    • 4.4.1 Opportunity1
    • 4.4.2 Opportunity 2
  • 4.5 Porters Five Force Model
  • 4.6 Value Chain Analysis
  • 4.7 Pricing Analysis
  • 4.8 Macroeconomic Analysis

5 GLOBAL EXTRACORPOREAL MEMBRANE OXYGENATION MACHINE MARKET, BY COMPONENT

  • 5.1 Overview
  • 5.2 Pumps
  • 5.3 Cannula
  • 5.4 Oxygenator
  • 5.5 Accessories
  • 5.6 Controller

6 GLOBAL EXTRACORPOREAL MEMBRANE OXYGENATION MACHINE MARKET, BY SERVICES

  • 6.1 Overview
  • 6.2 Veno- Arterial
  • 6.3 Veno-Venous
  • 6.4 Arterio-Venous

7 GLOBAL EXTRACORPOREAL MEMBRANE OXYGENATION MACHINE MARKET, BY PATIENT TYPE

  • 7.1 Overview
  • 7.2 Adult
  • 7.3 Pediatric
  • 7.4 Neonates

8 GLOBAL EXTRACORPOREAL MEMBRANE OXYGENATION MACHINE MARKET, BY APPLICATION

  • 8.1 Overview
  • 8.2 Respiratory
    • 8.2.1 Neonates
    • 8.2.2 Pediatric
    • 8.2.3 Adult
  • 8.3 ECPR
    • 8.3.1 Neonates
    • 8.3.2 Pediatric
    • 8.3.3 Adult
  • 8.4 Cardiac
    • 8.4.1 Neonates
    • 8.4.2 Pediatric
    • 8.4.3 Adult

9 GLOBAL EXTRACORPOREAL MEMBRANE OXYGENATION MACHINE MARKET, BY GEOGRAPHY

  • 9.1 Overview
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 U.K.
    • 9.3.3 France
    • 9.3.4 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Argentina
    • 9.5.3 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 UAE
    • 9.6.2 Saudi Arabia
    • 9.6.3 South Africa
    • 9.6.4 Rest of Middle-East and Africa

10 GLOBAL EXTRACORPOREAL MEMBRANE OXYGENATION MACHINE MARKET COMPETITIVE LANDSCAPE

  • 10.1 Overview
  • 10.2 Company Market Ranking
  • 10.3 Key Developments
  • 10.4 Company Regional Footprint
  • 10.5 Company Industry Footprint
  • 10.6 ACE Matrix

11 COMPANY PROFILES

  • 11.1 Medtronic
    • 11.1.1 Company Overview
    • 11.1.2 Company Insights
    • 11.1.3 Product Benchmarking
    • 11.1.4 Key Developments
    • 11.1.5 Winning Imperatives
    • 11.1.6 Current Focus & Strategies
    • 11.1.7 Threat from Competition
    • 11.1.8 SWOT Analysis
  • 11.2 Fresenius Medical Care A.G. & Co. KGAA
    • 11.2.1 Company Overview
    • 11.2.2 Company Insights
    • 11.2.3 Product Benchmarking
    • 11.2.4 Key Developments
    • 11.2.5 Winning Imperatives
    • 11.2.6 Current Focus & Strategies
    • 11.2.7 Threat from Competition
    • 11.2.8 SWOT Analysis
  • 11.3 Maquet Holding
    • 11.3.1 Company Overview
    • 11.3.2 Company Insights
    • 11.3.3 Product Benchmarking
    • 11.3.4 Key Developments
    • 11.3.5 Winning Imperatives
    • 11.3.6 Current Focus & Strategies
    • 11.3.7 Threat from Competition
    • 11.3.8 SWOT Analysis
  • 11.4 Getinge Group
    • 11.4.1 Company Overview
    • 11.4.2 Company Insights
    • 11.4.3 Product Benchmarking
    • 11.4.4 Key Developments
    • 11.4.5 Winning Imperatives
    • 11.4.6 Current Focus & Strategies
    • 11.4.7 Threat from Competition
    • 11.4.8 SWOT Analysis
  • 11.5 Microport
    • 11.5.1 Company Overview
    • 11.5.2 Company Insights
    • 11.5.3 Product Benchmarking
    • 11.5.4 Key Developments
    • 11.5.5 Winning Imperatives
    • 11.5.6 Current Focus & Strategies
    • 11.5.7 Threat from Competition
    • 11.5.8 SWOT Analysis
  • 11.6 Origin Biomedical
    • 11.6.1 Company Overview
    • 11.6.2 Company Insights
    • 11.6.3 Product Benchmarking
    • 11.6.4 Key Developments
    • 11.6.5 Winning Imperatives
    • 11.6.6 Current Focus & Strategies
    • 11.6.7 Threat from Competition
    • 11.6.8 SWOT Analysis
  • 11.7 Terumo Cardiovascular Systems Corporation
    • 11.7.1 Company Overview
    • 11.7.2 Company Insights
    • 11.7.3 Product Benchmarking
    • 11.7.4 Key Developments
    • 11.7.5 Winning Imperatives
    • 11.7.6 Current Focus & Strategies
    • 11.7.7 Threat from Competition
    • 11.7.8 SWOT Analysis
  • 11.8 Livanova plc
    • 11.8.1 Company Overview
    • 11.8.2 Company Insights
    • 11.8.3 Product Benchmarking
    • 11.8.4 Key Developments
    • 11.8.5 Winning Imperatives
    • 11.8.6 Current Focus & Strategies
    • 11.8.7 Threat from Competition
    • 11.8.8 SWOT Analysis
  • 11.9 Nipro Corporation
    • 11.9.1 Company Overview
    • 11.9.2 Company Insights
    • 11.9.3 Product Benchmarking
    • 11.9.4 Key Developments
    • 11.9.5 Winning Imperatives
    • 11.9.6 Current Focus & Strategies
    • 11.9.7 Threat from Competition
    • 11.9.8 SWOT Analysis
  • 11.10 Euro sets S.R.L.
    • 11.10.1 Company Overview
    • 11.10.2 Company Insights
    • 11.10.3 Product Benchmarking
    • 11.10.4 Key Developments
    • 11.10.5 Winning Imperatives
    • 11.10.6 Current Focus & Strategies
    • 11.10.7 Threat from Competition
    • 11.10.8 SWOT Analysis

12 VERIFIED MARKET INTELLIGENCE

  • 12.1 About Verified Market Intelligence
  • 12.2 Dynamic Data Visualization